Prophylaxis and therapy of pandemic H1N1 virus infection using egg yolk antibody

Journal of Virological Methods

Volumn 206, Issue , 2014, Pages 19-26

  Yang, Yuan e ^a   Wen, Junlin ^a   Zhao, Suqing ^a   Zhang, Kun ^a   Zhou, Yingliang ^b  

^a GUANGDONG UNIVERSITY OF TECHNOLOGY   (China)

^b Syracuse University   (United States)

Author keywords

Antiviral; Egg yolk antibody (IgY); Immunoprophylaxis; Immunotherapy; Pandemic H1N1 influenza virus

Indexed keywords

IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN Y ANTIBODY; INFLUENZA VIRUS HEMAGGLUTININ; OSELTAMIVIR; UNCLASSIFIED DRUG; VIRUS SIALIDASE; IMMUNOGLOBULIN; IMMUNOGLOBULIN Y; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMAGGLUTINATION INHIBITION TEST; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; LUNG PARENCHYMA; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN BINDING; TISSUE STRUCTURE; TREATMENT DURATION; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TITRATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BODY WEIGHT; DISEASE MODEL; EGG YOLK; HUMAN; IMMUNOLOGY; LUNG; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; PROCEDURES; SERODIAGNOSIS; TREATMENT OUTCOME; VIRAL PLAQUE ASSAY; VIROLOGY; VIRUS LOAD;

ANIMALS; ANTIBODIES, VIRAL; BODY WEIGHT; DISEASE MODELS, ANIMAL; EGG YOLK; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; INFLUENZA A VIRUS, H1N1 SUBTYPE; LUNG; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; TREATMENT OUTCOME; VIRAL LOAD; VIRAL PLAQUE ASSAY;

EID: 84902121357     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2014.05.016     Document Type: Article

References (34)

1. Ajlan A.M., Quiney B., Nicolaou S., Müller N.L. Swine-origin influenza A (H1N1) viral infection: radiographic and CT findings. Am. J. Roentgenol. 2009, 193:1494-1499.
2. Baz M., Abed Y., Papenburg J., Bouhy X., Hamelin M.-È., Boivin G. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N. Engl. J. Med. 2009, 361:2296-2297.
3. Chan P.K. Outbreak of avian influenza A (H5N1) virus infection in Hong Kong in 1997. Clin. Infect. Dis. 2002, 34:S58-S64.
4. Dai Y.C., Wang Y.Y., Zhang X.F., Tan M., Xia M., Wu X.B., Jiang X., Nie J. Evaluation of anti-norovirus IgY from egg yolk of chickens immunized with norovirus P particles. J. Virol. Methods 2012, 186:126-131.
5. Dai Y.C., Zhang X.F., Tan M., Huang P., Lei W., Fang H., Zhong W., Jiang X. A dual chicken IgY against rotavirus and norovirus. Antiviral Res. 2013, 97:293-300.
6. Devi C.M., Bai M.V., Lal A.V., Umashankar P.R., Krishnan L.K. An improved method for isolation of anti-viper venom antibodies from chicken egg yolk. J. Biochem. Biophys. Methods 2002, 51:129-138.
7. Ferguson N.M., Galvani A.P., Bush R.M. Ecological and immunological determinants of influenza evolution. Nature 2003, 422:428-433.
8. Gujral N., Lobenberg R., Suresh M., Sunwoo H. In-vitro and in-vivo binding activity of chicken egg yolk immunoglobulin Y (IgY) against gliadin in food matrix. J. Agric. Food Chem. 2012, 60:3166-3172.
9. Hoffmann E., Lipatov A.S., Webby R.J., Govorkova E.A., Webster R.G. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:12915-12920.
10. Hurt A.C., Ernest J., Deng Y.-M., Iannello P., Besselaar T.G., Birch C., Buchy P., Chittaganpitch M., Chiu S.-C., Dwyer D. Emergence and spread of oseltamivir-resistant A (H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antivir Res. 2009, 83:90-93.
11. Kollberg H., Carlander D., Olesen H., Wejaker P.E., Johannesson M., Larsson A. Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study. Pediatr. Pulmonol. 2003, 35:433-440.
12. Kovacs-Nolan J., Mine Y. Egg yolk antibodies for passive immunity. Ann. Rev. Food Sci. Technol. 2012, 3:163-182.
13. Landry M.L., Stanat S., Biron K., Brambilla D., Britt W., Jokela J., Chou S., Drew W.L., Erice A., Gilliam B., Lurain N., Manischewitz J., Miner R., Nokta M., Reichelderfer P., Spector S., Weinberg A., Yen-Lieberman B., Crumpacker C. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob. Agents Chemother. 2000, 44:688-692.
14. Liu D., Si B., Li C., Mi Z., An X., Qin C., Liu W., Tong Y. Prokaryotic expression and purification of HA1 and HA2 polypeptides for serological analysis of the 2009 pandemic H1N1 influenza virus. J. Virol. Methods 2011, 172:16-21.
15. Marcet I., Laca A., Paredes B., Díaz M. IgY isolation from a watery by-product obtained from an egg yolk fractionation process. Food Bioproducts Process. 2011, 89:87-91.
16. McCullers J.A. Insights into the interaction between influenza virus and pneumococcus. Clin. Microbiol. Rev. 2006, 19:571-582.
17. Nguyen H.H., Tumpey T.M., Park H.J., Byun Y.H., Tran L.D., Nguyen V.D., Kilgore P.E., Czerkinsky C., Katz J.M., Seong B.L., Song J.M., Kim Y.B., Do H.T., Nguyen T., Nguyen C.V. Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice. PLoS ONE 2010, 5:e10152.
18. Nilsson E., Kollberg H., Johannesson M., Wejaker P.E., Carlander D., Larsson A. More than 10 years' continuous oral treatment with specific immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: a case report. J. Med. Food 2007, 10:375-378.
19. Nilsson E., Larsson A., Olesen H.V., Wejaker P.E., Kollberg H. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr. Pulmonol. 2008, 43:892-899.
20. Patterson R., Youngner J.S., Weigle W.O., Dixon F.J. Antibody production and transfer to egg yolk in chickens. J. Immunol. 1962, 89:272-278.
21. Perez-Padilla R., De La Rosa-zamboni D., Ponce de Leon S., Hernandez M., Quiñones-Falconi F., Bautista E., Ramirez-Venegas A., Rojas-Serrano J., Ormsby C.E., Corrales A. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N. Engl. J. Med. 2009, 361:680-689.
22. Qiu D., Tannock G.A., Barry R.D., Jackson D.C. Western blot analysis of antibody responses to influenza virion proteins. Immunol. Cell Biol. 1992, 70(Pt 3):181-191.
23. Rimmelzwaan G., Baars M., Claas E., Osterhaus A. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J. Virol. Methods 1998, 74:57-66.
24. Ramirez-Gonzalez J.E., Gonzalez-Duran E., Alcantara-Perez P., Wong-Arambula C., Olivera-Diaz H., Cortez-Ortiz I., Barrera-Badillo G., Nguyen H., Gubareva L., Lopez-Martinez I. Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico. Emerg. Infect. Dis. 2011, 17:283.
25. Reed L.J., Muench H. A simple method for estimating fifty percent end points. Am. J. Epidemiol. 1938, 27:493-497.
26. Shin J.-H., Yang M., Nam S.W., Kim J.T., Myung N.H., Bang W.-G. Use of egg yolk-derived immunoglobulin as an alternative to antibiotic treatment for control of Helicobacter pylori infection. Clin. Diagn. Lab. Immunol. 2002, 9:1061-1066.
27. Tsukamoto M., Hiroi S., Adachi K., Kato H., Inai M., Konishi I., Tanaka M., Yamamoto R., Sawa M., Handharyani E., Tsukamoto Y. Antibodies against swine influenza virus neutralize the pandemic influenza virus A/H1N1. Mol. Med. Rep. 2011, 4:209-214.
28. Wyde P.R., Couch R.B., Mackler B.F., Cate T.R., Levy B.M. Effects of low-and high-passage influenza virus infection in normal and nude mice. Infect. Immun. 1977, 15:221-229.
29. Wallach M.G., Webby R.J., Islam F., Walkden-Brown S., Emmoth E., Feinstein R., Gronvik K.O. Cross-protection of chicken immunoglobulin Y antibodies against H5N1 and H1N1 viruses passively administered in mice. Clin. Vacc. Immunol. 2011, 18:1083-1090.
30. Wen J., Zhao S., He D., Yang Y., Li Y., Zhu S. Preparation and characterization of egg yolk immunoglobulin Y specific to influenza B virus. Antiviral Res. 2012, 93:154-159.
31. WHO Influenza Report by the Secretariat. Fifty-Sixth World Health Assembly. Provisional agenda item 1414 A56/23 17 March 2003 2003, http://apps.who.int/gb/archive/pdf_files/WHA56/ea5623.pdf.
32. WHO WHO: Global Alert and Response (GAR)-Pandemic (H1N1) 2009-update 101 2010.
33. Zhao S.Q., Sun Y.M., Zhang C.Y., Huang X.Y., Zhang H.R., Zhu Z.Y. Studies on purification of methamidophos monoclonal antibodies and comparative immunoactivity of purified antibodies. Biomed. Environ. Sci. 2003, 16:119-125.
34. Zhou B., Zhong N., Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N. Engl. J. Med. 2007, 357:1450-1451.